At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 target
Drug / intervention
Valsartant treatment +1 moredrug
Likely dose
Valsartant treatment 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.
In Brief
A Phase 4 clinical trial evaluating Continuous positive airway pressure (CPAP) and Valsartant treatment for Hypertension, and Obstructive Sleep Apnea. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The main objective of the study is to compare the decrease of mean arterial blood pressure over 24 hours in patients having obstructive sleep apnea syndrome and weak or moderate hypertension, treated by Valsartan 160mg per day versus continuous Positive Airway Pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension,, Obstructive Sleep Apnea
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
Primary CompletionDec 2006
First PostedDec 2006
Study CompletionMay 2009
TodayJul 2026
First PostedDec 11, 2006
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2006
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 19.6 years ago
Interventions
Continuous positive airway pressure (CPAP)device
8 weeks of CPAP
Valsartant treatmentdrug
8 weeks of Valsartant treatment (160 mg / day)